Supuran, and Jean-Yves Winum (eds.), Wiley, (2009).

“Histone Deacetylase Inhibitors”, in Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Claudiu T.

Peer Reviewed Publications (last 5 years) Paul also acts as a reviewer for many journals in the computational chemistry area and is as an expert evaluator for the EU Horizon 2020.

The development of cloud computing paradigms for molecular modelling research.

Development of computational methods to support phenotypic screening.

High-throughput virtual screening of massive cheminformatics databases.

Developing novel multi-dimensional methods for molecular similarity comparison.

Specific areas of ongoing research include: Paul’s research interests are in improving the efficiency and effectiveness of drug discovery through a combination of domain knowledge and research tools developed through multidisciplinary projects drawing on collaborative research in the areas for medicinal chemistry: computer science, robotics, mathematics and physics. Additionally, he remains CEO of InhibOx and runs a drug design consultancy Affinity Drug Design. Paul joined the staff at Buckingham as a Professorial Research Fellow in 2013, a joint appointment between the Clore Laboratory and Applied Computing Department. In 2004 Paul moved to InhibOx, a spin-out company from the Chemistry Department of the University of Oxford focused on computer-aided drug design. Following this acquisition Paul became group director of R&D and was responsible for TopoTarget’s extremely successful HDAC inhibitor programme which led to the discovery and development of Beleodaq™, which was granted approval for the treatment of relapsed or refractory PTCL by the FDA in July 2014. In 1998, Paul joined Prolifix, a UK biotechnology company which was acquired in 2002 by TopoTarget, a listed drug development company focused on oncology. In 1990, he moved to Pfizer’s computational chemistry group where he was responsible for developing Pfizer’s in-house approach to virtual screening. Paul completed his undergraduate biochemistry degree at St Peter’s College, Oxford in 1981 and holds a PhD from Manchester University (1985) on the prediction of protein structure by theoretical methods.īetween 19, Paul worked as a scientist in the computational chemistry group at SmithKline Beecham, where he focused on the discovery of novel antibiotic agents.

Fast by Lola Finn